Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)
NCT01024062
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG:
Paclitaxel
Sponsor
Bristol-Myers Squibb